New York, May 18, 2026, 09:08 EDT
Virax Biolabs Group Limited shares were indicated sharply higher before the Nasdaq open on Monday, adding to a gain at Friday’s close, after the microcap diagnostics company appeared in a weekend sponsored television segment and a fresh ownership filing hit the tape.
The move matters because Virax is a thinly valued, low-priced stock. StockAnalysis showed the shares closed Friday at $0.1535, up 9.64%, and were indicated at $0.3458 in pre-market trading at 8:59 a.m. EDT on Monday. Its market value at Friday’s close was about $3.06 million.
Pre-market trading is trading before the regular session; Nasdaq says its regular market opens at 9:30 a.m. ET and that extended-hours trading can be more volatile and less liquid, meaning fewer buyers and sellers may make prices move harder.
The latest catalyst was not a new clinical readout. RedChip Companies said Virax CEO James Foster appeared on its “Small Stocks, Big Money” show, a sponsored program on Bloomberg TV, on Saturday evening to discuss immune-function diagnostics for post-acute infection syndromes such as Long COVID and chronic fatigue syndrome. RedChip said Virax and Avalon Advanced Materials were clients. ACCESS Newswire
Virax is trying to build around ViraxImmune, a blood-based immune-profiling test. The company has described its U.S. entry plan as a laboratory-developed test, or LDT — a test designed and used within a single lab — with broader in vitro diagnostic, or IVD, development to follow. IVD refers to tests run on samples such as blood or tissue outside the body.
Foster said in an April shareholder letter that “our task is to execute,” and pointed to validation work and a U.S. market-entry path. The company said then that the next key milestone was a planned PAIS assay-performance data readout, with 2026 focused on readout and partner study preparation. Virax Biolabs Group Limited
The same filing said Virax’s UK PAIS studies were fully recruited, that U.S. clinical-validation planning with Emory University was under way, and that the company had achieved ISO 13485 and ISO 9001 certification. It also said ViraxImmune remained in development and was not approved for diagnostic use in any jurisdiction.
Separately, a Schedule 13G/A filed Friday showed Armistice Capital and Steven Boyd beneficially owned 1,000,239 Virax ordinary shares, representing 4.99% of the class. A Schedule 13G is a beneficial-ownership filing generally used by passive or institutional holders, not a statement that the investor controls the company.
The filing was accepted by the U.S. Securities and Exchange Commission on May 15 at 11:14 a.m., and Virax’s investor-relations filing page also listed it as the company’s latest SEC item.
There was no fresh company press release on the Virax investor-relations page over the weekend. The most recent company press release listed there was the April 14 shareholder letter, following a March 31 release on ISO certifications.
The competitive frame is diagnostics, not conventional drug development. Lucid Diagnostics, for example, markets the EsoGuard DNA test for esophageal precancer, a different disease area but a reminder that new diagnostics must clear not just science hurdles but also adoption, billing and physician-use hurdles.
The risk is that Monday’s move proves to be mostly trading flow. A paid media appearance, a passive ownership filing and a low float can draw attention, but they do not substitute for clinical validation, regulatory progress or revenue traction. If Virax’s PAIS data disappoints, if the LDT path takes longer than expected, or if the company needs more capital, the shares could give back the pre-market jump quickly.
